Aptose Biosciences - Senior VP, CFO Fletcher Payne
Senior VP, CFO Fletcher Payne
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Aptose Biosciences (APS) has appointed Fletcher Payne to the position of Senior Vice President & Chief Financial Officer (CFO)
  • Payne will lead Aptose’s financial operations and serve as a member of the Company’s executive management team
  • With a healthcare tenure of more than two decades, Payne most recently served as CFO of Syapse
  • Aptose Biosciences is a clinical-stage biotechnology company
  • Aptose Biosciences Inc. (APS) was down 3.70 per cent, trading at C$1.04 per share at 3:10 pm ET

Aptose Biosciences (APS) has appointed Fletcher Payne as Senior Vice President and Chief Financial Officer (CFO).

Payne will lead Aptose’s financial operations and serve as a member of the Company’s executive management team.

William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose commented on the appointment.

“As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry. It includes the equity capital markets, banking practices and financial transaction experience. We are delighted to have him join our executive management team and will benefit from his leadership, strategic insights, and guidance.”

With a healthcare tenure of more than two decades, Payne most recently served as CFO of Syapse. There he completed several financing transactions and oversaw accounting, finance, corporate development, and legal functions.

Previously, he has served as CFO at Catalyst Bioscience, a publicly traded biotech company. He served in a CFO capacity and senior financial positions at CytomX Therapeutics, Plexxikon Inc., Rinat Neuroscience Corporation, Dynavax Technologies Corporation, and Cell Genesys, among others. Payne holds a B.S. in Finance from the Haas School of Business, University of California, Berkeley.

Aptose Biosciences is a clinical-stage biotechnology company. It develops personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Aptose Biosciences Inc. (APS) was down 3.70 per cent, trading at C$1.04 per share at 3:10 pm ET.

More From The Market Herald
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.
Spectral Medical Inc. - CMO, Dr. John Kellum

" Spectral (TSX:EDT) gets FDA approval for Tigris trial

Spectral Medical (EDT) announced that the U.S. Food and Drug Administration (FDA) has approved ten new clinical trial sites for the Tigris trial.

" Diagnos (TSXV:ADK) receives approval for its AI enabled Pathology Detection Systems

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.

" BioHarvest (CSE:BHSC) launches first major U.S marketing campaign

BioHarvest Sciences (BHSC) has announced the first multimedia campaign for VINIA in the USA, Phase 1.